Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression

Siddhant U. Jain,Sima Khazaei,Dylan M. Marchione,Stefan M. Lundgren,Xiaoshi Wang,Daniel N. Weinberg,Shriya Deshmukh,Nikoleta Juretic,Chao Lu,C. David Allis,Benjamin A. Garcia,Nada Jabado,Peter W. Lewis
DOI: https://doi.org/10.1073/pnas.2006076117
IF: 11.1
2020-10-16
Proceedings of the National Academy of Sciences
Abstract:Significance A high frequency of missense mutations was recently discovered at histone H3.3 glycine 34 in 92% of giant cell tumors of the bone and 17% of high-grade astrocytomas. The molecular mechanism by which G34 mutations drive these tumors remains unclear. Here, we demonstrate that the G34-mutated “oncohistones” misregulate the negative cross-talk between two histone methyltransferase enzymes, Polycomb Repressive Complex 2 (PRC2) and SETD2. G34 mutations uniquely promote PRC2 activity by blocking SETD2-mediated H3K36 methylation at active enhancers and drive a gene expression program that enhances tumor growth. We propose that G34 oncohistones exploit the regulatory mechanisms that fine tune PRC2 activity in human malignancies.
multidisciplinary sciences
What problem does this paper attempt to address?